PhaseBio is dedicated to developing new therapies that improve the lives of people with serious rare diseases, with an initial focus on cardiopulmonary disorders. We are evaluating the potential benefit of our investigational therapies in clinical trials, in order to confirm their mechanisms of action in humans, to investigate their side effect profiles and to understand the characteristics of those patients most likely to benefit.
We are currently evaluating our lead therapy PB1046 in a phase 2a multiple ascending dose study in heart failure patients and in an exploratory individually dose-titrated study in subjects with pulmonary arterial hypertension. PhaseBio expects to initiate a phase 2 clinical study of PB1046 in PAH in early 2018.
Our goal is to work closely with patients and the scientific and regulatory communities to rapidly advance our pipeline and identify new therapeutic applications for our technology.